Neurocrine Biosciences | NBIX - Assets

Stock Price
137.15
Daily Change
-1.83 -1.32%
Monthly
0.85%
Yearly
-9.29%
Q1 Forecast
131.87

Neurocrine Biosciences reported $4.27B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Dynavax Technologies USD 946.51M 28.06M Sep/2025
Exelixis USD 2.82B 145.47M Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Incyte USD 6.33B 509M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Repligen USD 2.92B 22.08M Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025